Comparison of Recommended Screening Programs in the United States, Canada, the Netherlands and Germany

Dombrovskiy, V.S.; Khachatryan, G.

doi:10.17749/2070-4909.2016.9.4.046-053

Cited by 4 publications

(4 citation statements)

References 1 publication

(1 reference statement)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, many foreign countries with different types of health care systems are creating separate organizational structures to evaluate and select screening and other preventive interventions. The experience of the USA, UK, Germany, Turkey, Finland, as well as Belarus and Kazakhstan in conducting cancer screenings, is presented in Table 1 [4]. Countries with different types of health systems have separate structures on the national and local level that focus on the assessment and selection of screening and other preventive measures.…”

Section: Key Goals Of Screeningmentioning

confidence: 99%

“…Countries with different types of health systems have separate structures on the national and local level that focus on the assessment and selection of screening and other preventive measures. In the USA, Canada, Germany, Sweden, the Netherlands, there are state organizations on screening policy [4]. In the presence of such structures, the outcome depends on the appropriateness and effectiveness of screening programs, as well as on the interpretation of experts.…”

Section: Key Goals Of Screeningmentioning

confidence: 99%

See 1 more Smart Citation

How can cancer screening centers improve the healthcare system of Kazakhstan?

et al. 2021

View full text Add to dashboard Cite

This review article notes the importance of timely detection of cancer and precancerous diseases by screening. The key objective is to analyze screening approaches in developed countries. Results of the study of the experience, effectiveness, and current situation in the organization of cancer screening trials in the Republic of Kazakhstan are considered. The analysis has been performed based on published data on oncology screening carried out in Kazakhstan (2008Kazakhstan ( -2019 and independently collected data from the regions of the country. There is a tendency of growth of morbidity rate and decrease of mortality rate by screening localizations for the mentioned period. The percentage of detected malignant neoplasms is relatively low (from 15% in colorectal cancer screening to 35.4% in breast cancer screening). To study foreign experience in the organization of screening studies, the available data were taken from countries with different types of health care systems, including OECD countries (USA,

show abstract

Section: Key Goals Of Screeningmentioning

confidence: 99%

Section: Key Goals Of Screeningmentioning

confidence: 99%

How can cancer screening centers improve the healthcare system of Kazakhstan?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…У пациентов с ожирением значительно возрастает риск артериальной гипертензии (АГ), дислипидемии, сахарного диабета 2 типа (СД-2), ишемической болезни сердца, инсульта, желчекаменной болезни, остеоартрита, обструктивного апноэ сна, а также некоторых видов рака [6,7].…”

Section: Introductionunclassified

The use of telmisartan in patients with refractory arterial hypertension and obesity

Денека

Родионов

Fоmin

2019

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Aim. To evaluate the effectiveness of telmisartan as a component of triple antihypertensive therapy in patients with obesity and refractory arterial hypertension.Material and methods. The study included 30 patients with obesity and refractory arterial hypertension. All patients received an angiotensin II receptor blocker (ARB) or an angiotensin-converting enzyme inhibitor (ACE inhibitor) in an adequate dosage as part of a triple antihypertensive therapy that also includes a calcium antagonist and thiazide diuretic. Participants were randomly divided into two equal groups. In the main group, telmisartan (Dr. Reddy’s Laboratories) was prescribed at a dosage of 80 mg/day instead of the previously taken ARB or ACE inhibitor. In the control group, patients continued to receive a previously prescribed ARB or an ACE inhibitor. The primary end point was a decrease in mean daily systolic and/or diastolic blood pressure (SBP and DBP) according to 24-hour blood pressure monitoring at 10 mm Hg and more than 20 weeks after the start of the study. The secondary end point was a decrease in the concentration of inflammatory markers and an increase in the level of adiponectin by 15%.Results. After 20 weeks, in the telmisartan group, we noted a significant decrease in the average daily SBP and DBP: in the main group from 145,9±5,4/95,6±4,8 mm Hg to 134,8±3,0/84,9±4,2 mm Hg, in the control group with 147,2±4,9/96,4±5,6 mm Hg to 142,4±4,3/96,9±62 mm Hg. We also determined an increase in the serum adiponectin concentration from 9,3±5,6 μg/ml to 13,4±6,6 μg/ml in the main group and a decrease from 8,8±5,2 μg/ml to 8,6±5,6 μg/ml in the control group, as well as a decrease in the concentration of highly sensitive C-reactive protein (main group from 8,8±3,0 to 6,0±2,8 mg/l and the control group from 7,4±3,8 to 6,9±4,9 mg/l) and interleukin-6 (main group from 16,2±6,1 to 12,3±2,8 pg/ml, control group from 22,5±4,2 to 19,9±5,2 pg/ml).Conclusion. Telmisartan can be considered as a drug of choice as part of multi-component therapy in the treatment of patients with obesity and refractor arterial hypertension.

show abstract

“…Пристальное внимание исследователей к ожирению и метаболическому синдрому (МС) обусловлено тесной взаимосвязью этих патологий с такими жизнеугрожающими заболеваниями, как сахарный диабет (СД), инфаркт миокарда, сердечная недостаточность, инсульт, а также некоторыми видами рака [2][3][4][5].…”

unclassified

Treatment of hypertension in obese patients: focus on telmisartan

Денека

Родионов

Фомин

2018

Cardiovasc Ther Prev

View full text Add to dashboard Cite

The article discusses the role of telmisartan in the treatment of arterial hypertension in patients with metabolic syndrome. Telmisartan is second-generation type 1 angiotensin II receptor blocker, which has unique pleiotropic effects due to partial affinity for receptors that activate the proliferation of subtype γ peroxisomes (PPARγ) located in adipose tissue. The interrelation of metaflamation, a specific chronic inflammatory process with pathogenetic mechanisms of development of cardiovascular diseases, including arterial hypertension, is also described in study. The role of the adiponectin peptide is considered, which synthesis is stimulated by partial PPARγ receptor agonists (as mentioned above -telmisartan). It has a positive effect on fat and carbohydrate metabolism, as well as cardioprotective properties. The conclusion contains the results of numerous randomized studies and meta-analyzes confirming the high efficacy of telmisartan in the treatment of arterial hypertension in patients with morbid obesity.

show abstract

Comparison of Recommended Screening Programs in the United States, Canada, the Netherlands and Germany

Cited by 4 publications

References 1 publication

How can cancer screening centers improve the healthcare system of Kazakhstan?

How can cancer screening centers improve the healthcare system of Kazakhstan?

The use of telmisartan in patients with refractory arterial hypertension and obesity

Treatment of hypertension in obese patients: focus on telmisartan

Contact Info

Product

Resources

About